AbCellera Biologics Stock: Here’s What’s Coming in 2023

AbCellera Biologics Inc. (NASDAQ:ABCL) is a biotech stock that has explosive potential as we wade through the opening month of 2023.

| More on:
lab worker inspects test tubes

Source: Getty Images

AbCellera Biologics (NASDAQ:ABCL) is a Vancouver-based biotechnology company that develops an antibody discovery platform. Today, I want to discuss what lies ahead for this biotech stock in 2023 and beyond. Let’s jump in.

How has this biotech stock performed over the past year?

Biotech stocks have proven explosive but highly volatile over the past decade. AbCellera Biologics is no different. Shares of this biotech have climbed 6.9% year over year as of close on January 16. The stock has shot up 9.3% in the first weeks of the new year.

This biotech stock went public on the NASDAQ on December 11, 2020. It would suffer a steady decline in the months that followed its initial public offering (IPO). That said, it has shown some promise of late. Investors looking for a growth opportunity should look hard at AbCellera today.

Should you be excited about AbCellera’s future?

In 2021, Grand View Research estimated that the global biotechnology market was valued at US$1.02 trillion in 2021. The report projected that the global biotech market would deliver a compound annual growth rate (CAGR) of 13% from 2022 through to 2030. Investors should be eager to expose themselves to this promising market going forward.

More specifically, AbCellera has grown on the back of its industry leading engine for antibody discovery and development. Grand View Research also valued the global monoclonal antibodies market at US$185 billion in 2021. The report projects that this market will deliver a CAGR of 11% from 2022 through to 2030. This illustrates how explosive this biotech stock can be going forward.

Why investors should be encouraged by its most recent earnings

Investors can expect to see AbCellera’s final batch of fiscal 2022 results in the second half of February. This company released its third-quarter (Q3) fiscal 2022 earnings on November 8.

The company delivered total revenue of $101 million — up from $6 million in Q3 fiscal 2021. Meanwhile, cumulative program starts increased 33% to 92. AbCellera posted basic net earnings per share of $0.09 and diluted net earnings per share of $0.08 compared to a net loss of $0.08 per share (basic and diluted) in the prior year. Net income climbed to $26.6 million — up from $21.4 million in Q3 2021.

On the business front, programs under contract remained at a cumulative total of 164. Bebtelovimab is a monoclonal antibody that has been developed by AbCellera and Eli Lilly as a treatment for COVID-19. Royalties associated with bebtelovimab came to $93.3 million in Q3 2022, which made up the bulk of the company’s Q3 revenue. Better yet, the company closed out the quarter with strong liquidity of $868 million of cash, cash equivalents, and marketable securities.

AbCellera: Is this biotech stock worth buying today?

Shares of this exciting biotech stock are trading in favourable value territory at the time of this writing. Moreover, AbCellera is well positioned to deliver strong earnings growth in the quarters ahead. I’m looking to snatch up this promising stock after the midway point in January 2023.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Ambrose O'Callaghan has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends AbCellera Biologics. The Motley Fool has a disclosure policy.

More on Investing

analyze data
Investing

Better Buy: Shopify Stock vs. Aritzia

Growth stocks like Aritzia (TSX:ATZ) could outperform in the years ahead.

Read more »

A close up image of Canadian $20 Dollar bills
Dividend Stocks

Level Up Your Passive Income With 3 High-Yielding Stocks

Given their solid underlying businesses and high dividend yields, these three companies are an excellent buy for income-seeking investors.

Read more »

Man data analyze
Dividend Stocks

Beat the TSX With This Unstoppable Dividend Payer

BCE Inc. (TSX:BCE) could outperform the market with its dividend growth.

Read more »

Profit dial turned up to maximum
Dividend Stocks

Canadian Tire Stock Rose 15% in January 2023

Canadian Tire (TSX:CTC.A) stock continues to climb upwards yet still trades in value territory and with a solid dividend, as…

Read more »

healthcare pharma
Tech Stocks

Is Well Health Stock a Buy in February 2023?

WELL Health (TSX:WELL) stock is up 26% in the last month alone, but with full-year earnings still expected, that could…

Read more »

Canadian Dollars
Dividend Stocks

TFSA Investors: Where to Invest $6,500 in 2023

Here are three TSX stocks for TFSA investors.

Read more »

Payday ringed on a calendar
Dividend Stocks

Need $100? The Best Dividend Stocks for Monthly Income

These two dividend stocks are the best choices on the market if you want the best bang for your buck…

Read more »

Money growing in soil , Business success concept.
Dividend Stocks

3 Cheap Stocks for Premium Passive Income

These cheap stocks not only offer strong passive income, they also have been climbing higher in the last month.

Read more »